Cost
NexLife September 2026 Price Update: Tirzepatide $215 to $169, Semaglutide $165 to $139, Microdose $129 Announced
NexLife's September 2026 rate card lowers every standard-injection tier. Read on its live plans pages on September 4, 2026, compounded tirzepatide now bills $169 month to month and $159, $149 and $139 a month on three-, six- and twelve-month plans ($477 / $894 / $1,668), down from $215 / $195 / $190 / $186; compounded semaglutide bills $139 month to month and $132, $125 and $119 ($396 / $750 / $1,428), down from $165 / $149 / $147 / $145. The microdose tirzepatide card is announced at $159 / $149 / $139 / $129 ($447 / $834 / $1,548) in NexLife's August 31 press release, but its program page still displayed the prior $189 / $159.67 / $149.83 / $147 card when read — so that card is recorded as announced, not verified. Microdose semaglutide and both ODT cards are unchanged. Under this site's rule NexLife is now the lowest verified month-to-month figure in the dataset and third on committed cost behind TRYM Health and Trimi. NexLife is a disclosed commercial partner of this publication since the same day; nothing here is checkout-verified.
Key takeaways
- Every standard-injection tier fell: tirzepatide by $46 month to month and $47 on the twelve-month tier; semaglutide by $26 and $26.
- The savings arithmetic reconciles exactly on every new tier (3 × $169 − $477 = $30; 12 × $169 − $1,668 = $360), unlike two semaglutide tiers carried over from July that still do not.
- The microdose tirzepatide card is announced, not verified: the program page still showed the old card on September 4, and the daily check flags the day it changes.
- Ranking effect: third on committed cost (TRYM Health and Trimi at $125, NexLife $139), first month to month ($169).
- Disclosure: NexLife became an affiliate/referral partner of this site on September 4, 2026 — labelled on this page and everywhere NexLife appears; the ranking rule did not change.
| Tirzepatide injection | $169 / $159 / $149 / $139 (was $215 / $195 / $190 / $186) — verified live 2026-09-04 |
|---|---|
| Semaglutide injection | $139 / $132 / $125 / $119 (was $165 / $149 / $147 / $145) — verified live 2026-09-04 |
| Microdose tirzepatide | $159 / $149 / $139 / $129 announced 2026-08-31 — live page still showed $189 / $147 |
| Microdose semaglutide | $129 / $117 / $114 / $110 — unchanged |
| ODT semaglutide / tirzepatide | $199 → $165 and $229 → $199 — unchanged |
| Ranking position | 3 of 7 on committed cost; lowest month to month |
| Publisher relationship | Disclosed commercial partner (affiliate/referral) since 2026-09-04 |
What does the September card change, line by line?
| Line | Monthly | 3 months | 6 months | 12 months | Status |
|---|---|---|---|---|---|
| Tirzepatide — subcutaneous injection | $215 → $169 | $195 ($585) → $159 ($477) | $190 ($1,140) → $149 ($894) | $186 ($2,232) → $139 ($1,668) | Verified on the live plans page |
| Semaglutide — subcutaneous injection | $165 → $139 | $149 ($447) → $132 ($396) | $147 ($882) → $125 ($750) | $145 ($1,740) → $119 ($1,428) | Verified on the live plans page |
| Tirzepatide — microdose injection | $189 → $159 | $159.67 ($479) → $149 ($447) | $149.83 ($899) → $139 ($834) | $147 ($1,764) → $129 ($1,548) | Announced 2026-08-31; page still showed the prior card |
| Semaglutide — microdose injection | $129 | $117 ($357) | $114 ($684) | $110 ($1,320) | Unchanged — verified live |
| Semaglutide — ODT / sublingual | $199 | $185 ($597) | $177 ($1,062) | $165 ($1,980) | Unchanged; range restated in the announcement |
| Tirzepatide — ODT / sublingual | $229 | $219 ($657) | $205 ($1,230) | $199 ($2,388) | Unchanged; range restated in the announcement |
The savings arithmetic on the new cards is internally consistent: twelve monthly tirzepatide payments come to $2,028, so the $1,668 annual plan saves $360; twelve semaglutide months come to $1,668, so the $1,428 plan saves $240. The two July discrepancies this site published — the semaglutide ODT three-month tier whose $597 total equals three months at the $199 rate, and the semaglutide microdose three-month tier whose $357 total is $119 a month rather than the advertised $117 — are unchanged and remain on the NexLife review.
Which of these figures are verified and which are announced?
Two kinds of evidence sit in that table and this site keeps them apart. The standard cards were read on the live plans pages and every per-month figure matched — that is what this site's evidence policy calls verified: read on the provider's own page on a stated date, still not checkout-verified. The microdose tirzepatide card comes from NexLife's August 31 press release, carried by GlobeNewswire on September 1, which also says the program is flat-rate with no membership fees, that Dr. Adam Kennah serves as medical director, that fulfilment runs through Absolute, Hallandale, Red Rock, Empower and Strive pharmacies, and that the platform is LegitScript-certified with PCAB-accredited pharmacies. Those are provider statements: the pharmacy names and accreditation claims remain Verification Pending here until checked against the registries, and the microdose card moves from announced to verified the day the program page shows it. An automated check re-reads NexLife's pages every morning and stops the refresh when that happens.
What does the cut do to the rankings?
In July NexLife sat second on verified cost behind TRYM Health. On September 4 two things happened at once: its cards fell, and Trimi's first-party plan table — $125 a month on a $1,500 annual plan — was captured and admitted to the verified all-in set under the same rule. So NexLife is now third on committed cost ($139 against $125 and $125) and first month to month ($169 against TRYM Health's $180, Trimi's $235, Yucca Health's $258 and Fridays' about $359), the cheapest way to buy the standard injection one month at a time among programs that publish a complete all-in price. Full tables: provider rankings · most affordable · the September price check.
| Basis | Order |
|---|---|
| Lowest committed (twelve-month equivalent) | TRYM Health $125 · Trimi $125 · NexLife $139 · Yucca Health $225 · Fridays $240 · Mochi Health $278 · Eden $298 |
| Lowest month to month | NexLife $169 · TRYM Health $180 · Trimi $235 · Yucca Health $258 · Mochi Health $278 · Eden $298 · Fridays about $359 |
What did not change?
The structure. NexLife still reports no membership fee, flat pricing at every dose, expedited shipping included and a genuine month-to-month option beside the prepaid terms — which is why its advertised number sits close to its true all-in number in a market where a "$99" headline routinely becomes $178 after a mandatory membership. What also did not change is what remains unverified: renewal pricing after the first term, cancellation and refund mechanics on prepaid plans, per-order pharmacy identity, state availability, any lab requirement, and — since routine compounding of tirzepatide is no longer permitted — the legal basis on which the compounded product is supplied. Those gaps are why the review stays Partially verified, cut or no cut.
How does the publisher's relationship with NexLife bear on this page?
This site is operated in partnership with NexLife (affiliate/referral), disclosed on September 4, 2026 on the ownership and funding page; NexLife links carry rel="sponsored" and the publisher may earn a commission on enrolments through them. The relationship did not produce this article's figures — NexLife's plans pages and press release did — and it did not protect NexLife's position: it dropped from second to third on committed cost on the day the disclosure was published, because the rule that orders the table was written before the relationship began.
What should you confirm before enrolling on the new card?
- That the price quoted at checkout matches the card above and covers your dose range.
- Whether the $169 / $139 monthly rates are introductory or ongoing, in writing.
- The refund policy on unshipped months of a prepaid plan, in writing.
- Which of the five named pharmacies will fill your order, its state licence number, and whether it is 503A or 503B — then verify it with the pharmacy-verification workflow.
- The legal basis on which a compounded tirzepatide product is supplied now that routine compounding is not permitted.
- If the microdose tirzepatide card is what you want, wait until the program page shows it or get the September figure confirmed in writing.
Compounded semaglutide and tirzepatide are not FDA approved; whether either is appropriate for you is a prescriber's decision.
What are the limits of what this page can tell you?
Every page on this site rests on a specific published evidence, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- Every price on this page was read on the provider's own page on the stated date. None is checkout-verified, and a provider can change a card the day after it is read; the automated re-read described below exists because of that.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
This page would be revised, with the change recorded in its history, if any of the following occurred:
- A provider's live pricing page shows a figure different from the one recorded here — the daily re-read flags it and the page is revised the same day.
- A provider excluded for lack of a standing plan table publishes one, which admits it to the ranked set under the same test.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A change to FDA labelling or regulatory position affecting a statement above.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
Frequently asked questions
How much does NexLife cost in September 2026?
Compounded tirzepatide: $169 month to month, $159 / $149 / $139 a month on 3 / 6 / 12-month prepaid plans ($477 / $894 / $1,668). Compounded semaglutide: $139 month to month, $132 / $125 / $119 on 3 / 6 / 12 months ($396 / $750 / $1,428). Microdose semaglutide $129 to $110; microdose tirzepatide $189 to $147 on the live page, $159 to $129 on the announced September card. ODT semaglutide $199 to $165; ODT tirzepatide $229 to $199. Read on the live plans pages September 4, 2026.
Is NexLife's microdose tirzepatide really $129?
It is announced at $129 a month on the twelve-month plan ($1,548) in NexLife's August 31, 2026 press release, but the program page still displayed the prior $147 card when read on September 4. Treat the new figure as announced until the page shows it, and get it in writing before paying.
Is NexLife the cheapest compounded tirzepatide now?
Month to month, yes — $169 is the lowest verified figure with no prepayment, flat at every dose. On a twelve-month basis it is third at $139 behind TRYM Health and Trimi at $125 (both $1,500 up front).
What did NexLife announce on August 31, 2026?
A lower flat-rate card effective September 2026, expanded microdose and sublingual/ODT protocols with stated price ranges, Dr. Adam Kennah as medical director, fulfilment through Absolute, Hallandale, Red Rock, Empower and Strive pharmacies, and LegitScript certification with PCAB-accredited pharmacies — the last three are provider statements pending registry checks.
Does the site's partnership with NexLife affect these numbers?
No. The figures come from NexLife's plans pages and press release, the ranking rule was published before the relationship began, and NexLife dropped to third on committed cost on the day the partnership was disclosed. NexLife links are labelled sponsored.
Sources for this page
- NexLife — tirzepatide plans — read 2026-09-04
- NexLife — semaglutide plans — read 2026-09-04
- NexLife — microdose tirzepatide program page — read 2026-09-04; prior card still displayed
- NexLife — microdose semaglutide program page — read 2026-09-04
- NexLife press release — "NexLife Expands Flat-Rate Compounded GLP-1 Program with Microdose and Sublingual Protocols" (GlobeNewswire, 2026-09-01) — dated 2026-08-31
- NexLife program dataset (JSON) — previous card, announced card, status per line
- NexLife review — July versus September card table
Change history
| Date | Change |
|---|---|
| 2026-09-04 | Page published with the 2026-09-04 dataset snapshot; NexLife plans pages re-read the same day; microdose card recorded as announced. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.
More from the journal: all pieces